Insiders who purchased this year lose US$89k as Aptose Biosciences Inc. (TSE:APS) stock drops to CA$1.44
Insiders who bought US$160k worth of Aptose Biosciences Inc.'s (TSE:APS) stock at an average buy price of US$3.25 over the last year may be disappointed by the recent 45% decrease in the stock. This is not good as insiders invest based on expectations that their money will appreciate over time. However, as a result of recent losses, their original investment is now worth only US$71k.
Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.
Check out our latest analysis for Aptose Biosciences
The Last 12 Months Of Insider Transactions At Aptose Biosciences
Over the last year, we can see that the biggest insider sale was by the Independent Director, Warren Whitehead, for CA$83k worth of shares, at about CA$3.35 per share. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The good news is that this large sale was at well above current price of CA$1.44. So it may not tell us anything about how insiders feel about the current share price. The only individual insider seller over the last year was Warren Whitehead.
In the last twelve months insiders purchased 49.45k shares for CA$160k. On the other hand they divested 25.00k shares, for CA$83k. Overall, Aptose Biosciences insiders were net buyers during the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
Aptose Biosciences Insiders Bought Stock Recently
Over the last quarter, Aptose Biosciences insiders have spent a meaningful amount on shares. Not only was there no selling that we can see, but they collectively bought CA$116k worth of shares. That shows some optimism about the company's future.
Insider Ownership of Aptose Biosciences
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. From our data, it seems that Aptose Biosciences insiders own 5.1% of the company, worth about CA$11m. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!
What Might The Insider Transactions At Aptose Biosciences Tell Us?
It's certainly positive to see the recent insider purchases. We also take confidence from the longer term picture of insider transactions. But we don't feel the same about the fact the company is making losses. Given that insiders also own a fair bit of Aptose Biosciences we think they are probably pretty confident of a bright future. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Every company has risks, and we've spotted 2 warning signs for Aptose Biosciences (of which 1 is a bit concerning!) you should know about.
But note: Aptose Biosciences may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
